lncRNA CISAL Inhibits BRCA1 Transcription by Forming a Tertiary Structure at Its Promoter

Volume: 23, Issue: 2, Pages: 100835 - 100835
Published: Feb 1, 2020
Abstract
Cisplatin-based neoadjuvant chemotherapy has been shown to improve survival in patients with squamous cell carcinoma (SCC), but clinical biomarkers to predict chemosensitivity remain elusive. Here, we show the long noncoding RNA (lncRNA) LINC01011, which we termed cisplatin-sensitivity-associated lncRNA (CISAL), controls mitochondrial fission and cisplatin sensitivity by inhibiting BRCA1 transcription in tongue SCC (TSCC) models....
Paper Details
Title
lncRNA CISAL Inhibits BRCA1 Transcription by Forming a Tertiary Structure at Its Promoter
Published Date
Feb 1, 2020
Journal
Volume
23
Issue
2
Pages
100835 - 100835
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.